ValuEngine upgraded shares of Myovant Sciences (NYSE:MYOV) from a sell rating to a hold rating in a report released on Wednesday.
Separately, Zacks Investment Research raised Myovant Sciences from a sell rating to a hold rating in a research note on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Myovant Sciences presently has a consensus rating of Hold and an average price target of $21.00.
Myovant Sciences stock opened at $21.20 on Wednesday. Myovant Sciences has a 1 year low of $9.92 and a 1 year high of $24.14. The company has a current ratio of 5.04, a quick ratio of 5.04 and a debt-to-equity ratio of 0.35.
In other news, major shareholder Pharmaceuticals Interna Takeda bought 7,420,625 shares of the firm’s stock in a transaction on Monday, March 19th. The stock was acquired at an average price of $18.67 per share, with a total value of $138,543,068.75. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Holdings Ltd. Dexxon bought 1,110,015 shares of the firm’s stock in a transaction on Monday, April 2nd. The shares were purchased at an average cost of $20.27 per share, with a total value of $22,500,004.05. The disclosure for this purchase can be found here. Corporate insiders own 3.00% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. acquired a new stake in Myovant Sciences during the 3rd quarter valued at approximately $1,255,000. Ardsley Advisory Partners acquired a new stake in Myovant Sciences during the 4th quarter valued at approximately $1,272,000. Finally, JPMorgan Chase & Co. increased its position in Myovant Sciences by 18.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock valued at $1,382,000 after purchasing an additional 14,203 shares during the period. 81.44% of the stock is owned by institutional investors and hedge funds.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.